Getting a traditional pharmaceutical to the market can cost a billion dollars or more. Newer, more tailored and targeted drugs called biologics are even more complex and expensive. Simple economics dictates that companies and venture funds will invest more in products that can generate a sufficient return.

Those of us who lived through the worst of the HIV/AIDS epidemic from the early 1980s through the mid-1990s have a very special spot in our heart for home-based health care.

I'd come to the country to do my Thoreau bit, so I needed an office that looked out onto the woods for inspiration. I converted one of the bedrooms into my workspace and through its windows watched the wildlife appear each morning with the sunrise. Many were the days I would sit in wonder, coffee in hand, for hours.

Change comes with both fear and some pain. Those two ingredients create mistrust, misunderstanding and misinformation. Such is the process of democracy.

At 60, the mind was sharp but the body complained. The legs were willing to make all the right moves but the muscles gave out too early.

For many people with HIV, finding the right doctor is the most important decision they'll make.

Getting a traditional pharmaceutical to the market can cost a billion dollars or more. Newer, more tailored and targeted drugs called biologics are even more complex and expensive. Simple economics dictates that companies and venture funds will invest more in products that can generate a sufficient return.